Business
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
WESTMINSTER, Colo., January 12, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"Fourth quarter 2025 revenue of approximately $13.2 million, Up 60% Year-Over-Year","length":81,"tagName":"p","attribs":{}},{"type":"text","content":"Full-year 2025 revenue growth of approximately 53% exceeded 2025 guidance","length":73,"tagName":"p","attribs":{}},{"type":"text","content":"Set initial 2026 revenue guidance of approximately $60-$62 million","length":66,"tagName":"p","attribs":{}},{"type":"text","content":"WESTMINSTER, Colo., January 12, 2026--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.","length":445,"tagName":"p"},{"type":"text","content":"The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and full-year 2025 revenues of approximately $45.2 million. As of December 31, 2025, TriSalus estimates cash and cash equivalents of approximately $20.4 million.","length":245,"tagName":"p"},{"type":"text","content":""TriSalus continued to deliver strong commercial performance in the fourth quarter and exceeded our 2025 guidance of 50% annual revenue growth, underscoring the meaningful clinical adoption of our TriNav® product suite and proprietary PEDD® platform across a broad range of solid tumor indications," said Mary Szela, President and Chief Executive Officer of TriSalus. "We are pleased not only with our commercial execution but also with the sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver and deepening our engagement within the interventional radiology community. Looking ahead to 2026, we expect full-year revenues to be in a range of approximately $60 million to $62 million."","length":788,"tagName":"p"},{"type":"text","content":"Projected Unaudited 2025 Fourth Quarter and Full-Year Financial Results","length":71,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Preliminary revenue for the fourth quarter of approximately $13.2 million, compared to $8.3 million in the prior year, representing approximat...